ClinicalTrials.gg

Program

ENX-102

A development code.

Its studies are mostly in Generalized Anxiety Disorder · Phobia, Social, led by Engrail Therapeutics.

Furthest: phase 2, since Feb 18, 20233 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Engrail Therapeutics30 open or runningphase 2since Feb 18, 2023Feb 18, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 18, 2023First study: phase 2 study in Generalized Anxiety DisorderFirst studyNCT05749055 · 252 enrolled · United States
  2. Oct 20, 2024Phase 2 study in Generalized Anxiety DisorderNCT06653296 · 38 enrolled · United Kingdom
  3. Sep 24, 2025Phase 2 study in Phobia, SocialNCT07193563 · 47 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07193563Phobia, Social · United States2CompletedMar 19, 202647
NCT06653296Generalized Anxiety Disorder · United Kingdom2CompletedJun 23, 202538
NCT05749055Generalized Anxiety Disorder · United States2CompletedSep 18, 2025252

How it is read

Names in the registry

  • “ENX-102”, 3 entries

Codes read as this program: ENX102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.